Anastasios Gianakakos Sells 4,300 Shares of MyoKardia, Inc. (MYOK) Stock
MyoKardia, Inc. (NASDAQ:MYOK) insider Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $43.02, for a total transaction of $184,986.00. Following the completion of the sale, the insider now owns 512,463 shares of the company’s stock, valued at approximately $22,046,158.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Anastasios Gianakakos also recently made the following trade(s):
- On Friday, August 4th, Anastasios Gianakakos sold 4,300 shares of MyoKardia stock. The shares were sold at an average price of $16.62, for a total transaction of $71,466.00.
- On Tuesday, July 25th, Anastasios Gianakakos sold 32,988 shares of MyoKardia stock. The shares were sold at an average price of $15.00, for a total transaction of $494,820.00.
Shares of MyoKardia, Inc. (NASDAQ:MYOK) traded up 4.69% on Thursday, hitting $43.50. 409,898 shares of the stock were exchanged. The company’s 50 day moving average is $31.57 and its 200-day moving average is $17.88. The stock’s market cap is $1.37 billion. MyoKardia, Inc. has a 52-week low of $10.55 and a 52-week high of $46.80.
MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. MyoKardia had a negative return on equity of 16.35% and a negative net margin of 44.65%. The company had revenue of $5.60 million for the quarter, compared to analyst estimates of $6.73 million. During the same period in the previous year, the business posted ($0.37) EPS. The firm’s revenue for the quarter was up 60.0% compared to the same quarter last year. Analysts predict that MyoKardia, Inc. will post ($1.64) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/07/anastasios-gianakakos-sells-4300-shares-of-myokardia-inc-myok-stock.html.
A number of hedge funds have recently added to or reduced their stakes in MYOK. Wellington Management Group LLP raised its holdings in MyoKardia by 12.5% during the first quarter. Wellington Management Group LLP now owns 3,154,734 shares of the biotechnology company’s stock worth $41,485,000 after purchasing an additional 349,768 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in MyoKardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after purchasing an additional 242,408 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in MyoKardia during the second quarter worth approximately $1,757,000. Marshall Wace North America L.P. acquired a new stake in MyoKardia during the first quarter worth approximately $1,577,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in MyoKardia during the first quarter worth approximately $1,577,000. 48.38% of the stock is currently owned by institutional investors.
MYOK has been the subject of several recent research reports. BidaskClub upgraded shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. BMO Capital Markets restated an “outperform” rating and issued a $65.00 price target (up previously from $45.00) on shares of MyoKardia in a report on Monday, August 21st. TheStreet lowered shares of MyoKardia from a “c-” rating to a “d+” rating in a report on Friday, May 19th. Cowen and Company boosted their price target on shares of MyoKardia from $28.00 to $56.00 and gave the company an “outperform” rating in a report on Monday, August 7th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $48.00 price target (up previously from $31.00) on shares of MyoKardia in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. MyoKardia currently has an average rating of “Buy” and an average price target of $41.60.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.